National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
Institute of Hematology & Blood Diseases Hospital, China
1,000 participants
Jun 1, 2021
OBSERVATIONAL
Conditions
Summary
This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.
Eligibility
Inclusion Criteria3
- Patients with clinically diagnosed hematologic malignancies
- Patients treated with CAR-T cell therapy
- Signed the informed consent form
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06607289